Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Rituximab is an effective treatment for Sjögren's syndrome

Nature Clinical Practice Rheumatology volume 1, pages 68–69 (2005)Cite this article

Pijpe J et al. (2005) Rituximab treatment in patients with primary Sjögren's syndrome. Arthritis Rheum 52: 2740–2750

There are currently no evidence-based treatments for Sjögren's syndrome (SS), an autoimmune disease characterized by chronic inflammation of the salivary and lacrimal glands that leads to malignant B-cell lymphoma in 5% of patients. Salivary gland function attenuates early in the disease, accompanied by altered salivary composition. Although associated with side effects and the production of antichimeric antibodies, the anti-CD20 monoclonal antibody rituximab has shown promise in the treatment of SS in this small, open-label, phase II study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Rebecca Doherty
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doherty, R. Rituximab is an effective treatment for Sjögren's syndrome. Nat Rev Rheumatol 1, 68–69 (2005). https://doi.org/10.1038/ncprheum0027

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0027

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing